Relationship between the factorⅩⅢ (F Ⅹ Ⅲ ) gene polymorphisms and pulmonary thromboembolism in Chinese Han population

doi:10.3969/j.issn.1006-7795.2013.01.026

Abstract

Abstract:

Objective To determine the prevalence of F Ⅹ Ⅲ A Val34Leu (100G/T) and F Ⅹ Ⅲ B His95Arg (8259A/G) polymorphisms in Chinese Han population and to investigate whether they were associated with pulmonary thromboembolism pulmonary thromboembolism(PTE).Methods The subjects consisted of 114 patients with PTE and 114 healthy controls matched in age, sex and race. All patients were diagnosed by lung ventilation/perfusion scan and/or multi-slice CT pulmonary angiography. Genome DNA was extracted from whole blood using phenol-chloroform. Genotypes and allele frequencies of F Ⅹ Ⅲ A Val34Leu (100G/T) and F Ⅹ Ⅲ B His95Arg (8259A/G) polymorphisms were examined by PCR-RFLP. Results Regarding F Ⅹ Ⅲ A Val34Leu and F Ⅹ Ⅲ B His95Arg polymorphisms,the allele frequencies G and T of F Ⅹ Ⅲ A Val34Leu in the controls were 0.996, 0.004, while A and G of F Ⅹ Ⅲ B His95Arg were 0.956, 0.044 respectively, which were in good agreement with Hardy-Weinberg equilibrium. The genotype TT (Leu/Leu) of F Ⅹ Ⅲ A Val34Leu polymorphisms was not detected. The distributions of genotype GG (Val/Val), GT (Val/Leu) were similar between the patients and controls. The genotype GG (Arg/Arg) of F Ⅹ Ⅲ B His95Arg polymorphisms was not detected. The genotype AG (His/Arg) was a protective factor for PTE patients (OR=0.281, 95%CI: 0.075-1.050( P=0.046). Conclusion The allele T (Leu) of F Ⅹ Ⅲ A Val34Leu polymorphism is rare and may be not association with PTE in Chinese Han population. The genotype AG (His/Arg) of F Ⅹ Ⅲ B His95Arg may be a protective factor for PTE patients.

Key words: pulmonary embolism, thromboembolism, factor ⅩⅢ, polymorphism, single nucleotide

CLC Number:

R563.5

XU Xiaoyan, YANG Yuanhua, ZHAI Zhenguo, PANG Baosen, WANG Chen. Relationship between the factorⅩⅢ (F Ⅹ Ⅲ ) gene polymorphisms and pulmonary thromboembolism in Chinese Han population[J]. Journal of Capital Medical University, 2013, 34(1): 134-139.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2013.01.026

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2013/V34/I1/134

References

[1] Voetsch B, Loscalzo J. Genentic determinants of artierial thrombosis[J]. Thromb Vasc Biol, 2004, 24: 226-229.

[2] Voko Z, Bereczky Z, Katona E, et al. Factor ⅩⅢ Val34Leu variant protects against coronary artery disease: A meta-analysis[J]. Thromb Haemost, 2007, 97(3):458-463.

[3] Shafey M, Anderson J L, Scarvelis D, et al. Factor ⅩⅢ Val34Leu variant and the risk of myocardial infarction-A meta-analysis[J]. Thromb Haemost,2007, 97(4): 635-641.

[4] Wells P S, Anderson J L, Scarvelis D K, et al. Factor ⅩⅢ Val34Leu variant is protective against venous thromboembolism: a HuGE review and Meta-Analysis[J]. Am J Epidemiol, 2006, 164(2): 101-109.

[5] Gohil R, Peck G, Sharma P. The genetics of venous thromboembolism. A meta-analysis involving approximately 120,000 cases and 180,000 controls[J]. Thromb Haemost, 2009,102(2): 360-370.

[6] Reiner A P, Heckbert S R, Vos H L, et al. Genetic variants of coagulation factor ⅩⅢ, postmenopausal estrogen therapy, and risk of nonfatal myocardial infarction[J]. Blood, 2003, 102(1): 25-30.

[7] Komanasin N, Catto A J, Futers T S, et al. A novel polymorphism in the factor ⅩⅢ B-subunit (His95Arg): relationship to subunit dissociation and venous thrombosis[J]. J Thromb haemost, 2005, 3(11): 2487-2496.

[8] 中华医学会呼吸病学分会. 肺血栓栓塞症的诊断与治疗指南(草案)[J]. 中华结核和呼吸杂志, 2001, 24: 259-264.

[9] Kangsadalampai S, Board P G. The Val34Leu polymorphism in the a subunit of coagulation factor ⅩⅢ contributes to the large normal range in activity and demonstrates that the activation peptide plays a role in catalytic activity[J]. Blood, 1998, 92(8): 2766-2770.

[10] Scott E M, Ariёns R, Grant P J. Genetic and Environmental Determinants of Fibrin Structure and Function: Relevance to Clinical Disease[J]. Arterioscler Thromb Vasc Biol,2004, 24(19):1558-1566.

[11] Balogh I, Szoke G, Karpati L, et al. Val34Leu polymorphism of plasma factor ⅩⅢ: biochemistry and epidemiology in familial thrombophilia[J]. Blood, 2000, 96(17): 2479-2486.

[12] Ariens R A, Philippou H, Nagaswami C, et al. The factor ⅩⅢ V34L polymorphism accelerates thrombin activation of factor ⅩⅢ and affects cross-linked fibrin structure[J]. Blood, 2000, 96(3): 988-995.

[13] Ariens R A, Lai T S, Weisel J W, et al. Role of factor ⅩⅢ in fibrin clot formation and effects of genetic polymorphisms[J]. Blood, 2002, 100(3):743-754.

[14] Shemirani A H, Haramura G, Bagoly Z, et al. The combined effect of fibrin formation and factor ⅩⅢ A subunit Val34Leu polymorphism on the activation of factor ⅩⅢ in whole plasma[J]. Biochim Biophys Acta,2006, 1764(8):1420-1423.

[15] Bagoly Z, Koncz Z, Hársfalvi J, et al. Factor ⅩⅢ, clot structure, thrombosis[J].Thromb Res, 2012, 129(3):382-387.

[16] Attié-Castro FA, Zago M A, Lavinha J, et al. Ethnic heterogeneity of the factor ⅩⅢ Val34Leu polymorphism[J]. Thromb Haemost, 2000, 84(4):601-603.

[17] 郑红, 贺颖, 连建华,等. 深静脉血栓形成患者凝血因子III Val34Leu基因多态性检测[J]. 郑州大学学报:医学版, 2006, 41(2): 280-282.